文献速递生殖医学

比较离子霉素与A23187在受精失败或受精受损风险患者中行人工卵母细胞激活的效果

Artificial oocyte activation with ionomycin compared with A23187 among patients at risk of failed or impaired fertilization.
PubMed 文献 · Reprod Biomed Online · 2022-08-25

这项单中心7年回顾性队列研究纳入157对夫妇、171个ICSI-AOA周期,比较10 µmol/l离子霉素与商品化A23187的胚胎学与临床结局;离子霉素组在全部三个亚组的受精率均显著更高,但第3天优质胚胎率、临床妊娠率、着床率、活产率及累积活产率两组无显著差异,共获64例活产、72名健康婴儿。

要点

  • 离子霉素组受精率在全部三个亚组均显著高于A23187组。
  • 低受精组离子霉素第3天卵裂率显著更高,另两组无显著差异。
  • 两组第3天优质胚胎率、临床妊娠率、着床率、活产率及累积活产率均无显著差异。

核心结论

  • 对于受精失败或受精受损风险患者,10 µmol/l离子霉素行AOA在改善卵母细胞激活方面可能比商品化A23187更有效,尤其在精子相关缺陷病例中。

研究设计与样本

  • 单中心、为期7年的回顾性队列研究,纳入157对夫妇,均有ICSI后完全受精失败(TFF,0%)或低受精(<30%)史,或男方患严重少弱畸精子症(OAT)。
  • 共行171个ICSI-AOA周期,分别使用10 µmol/l离子霉素或商品化A23187,比较胚胎学与临床结局。

主要发现

  • TFF亚组受精率离子霉素组46.9% vs A23187组28.4%(P = 0.002)。
  • 低受精亚组受精率离子霉素组67.7% vs A23187组49.2%(P < 0.001)。
  • 严重OAT亚组受精率离子霉素组66.4% vs A23187组31.6%(P < 0.001)。
  • 低受精组第3天卵裂率离子霉素组显著高于A23187组(P = 0.009),TFF组与严重OAT组均无显著差异(均P > 0.05)。
  • 两组第3天优质胚胎率、临床妊娠率、着床率、活产率及累积活产率均无显著差异(均P > 0.05);共64例活产、72名健康婴儿出生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Do fertilization rates differ between intracytoplasmic sperm injection (ICSI) cycles treated with artificial oocyte activation (AOA) using 10 µmol/l ionomycin or commercial A23187 in women at risk of failed or impaired fertilization? DESIGN: This single-centre, 7-year retrospective cohort study included 157 couples with a history of total fertilization failure (TFF, 0%) or low fertilization (<30%) after ICSI, or with severe oligo-astheno-teratozoospermia (OAT) in the male partner. Couples and underwent 171 ICSI-AOA cycles using either 10 µmol/l ionomycin or commercial A23187. The embryological and clinical outcomes were compared. RESULTS: Fertilization rates in the ionomycin group were significantly higher than those in the A23187 group for all three subgroups (TFF, 46.9% versus 28.4%, P = 0.002; low fertilization, 67.7% versus 49.2%, P < 0.001; severe OAT, 66.4% versus 31.6%, P < 0.001). AOA with ionomycin significantly increased the day 3 cleavage rate (P = 0.009) when compared with A23187 in the low fertilization group, but not in the TFF or severe OAT group (both P > 0.05). The rates of day 3 good-quality embryos, clinical pregnancy, implantation and live birth, and the cumulative live birth, did not differ between the two groups (all P > 0.05). A total of 64 live births resulted in 72 healthy babies born. CONCLUSIONS: AOA with 10 µmol/l ionomycin may be more effective than commercial A23187 in improving oocyte activation in patients at risk of failed or impaired fertilization, especially in cases of sperm-related defects.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Jia L, Chen P, Su W, et al. Artificial oocyte activation with ionomycin compared with A23187 among patients at risk of failed or impaired fertilization. Reprod Biomed Online. 2022. PMID: 36379856. doi:10.1016/j.rbmo.2022.08.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。